🔴 Crispr Therapeutics AG is trading 4% down despite potentially positive FDA guidance for the gene therapy sector

Crispr Therapeutics AG is trading 4% down at $52.01, a move that comes amid mixed signals for the gene-editing sector. While the stock appears to be undergoing profit-taking after recent gains, the U.S. FDA today issued new draft guidance that could be a long-term positive for the industry.

• The FDA's new guidance is intended to accelerate the development of gene and cell therapies by allowing greater use of existing scientific and regulatory knowledge, which could benefit companies like CRISPR Therapeutics.
• The stock's decline today appears idiosyncratic as broad U.S. equity indices are flat, suggesting the movement may be driven by profit-taking or other company-specific factors rather than a negative reaction to the sector news.